Abstract: Disclosed is an apparatus for assisting steering at the time of parking which allows the driver to easily ascertain the steering timing and steering amount at the time of parking.

Abstract: Pyrrolopyridazine derivatives having the general formula. ##STR1## In the above formula, R.sup.1 represents a C.sub.2 -C.sub.6 alkenyl-group, a halogeno-C.sub.2 -C.sub.6 -alkenyl group, a C.sub.6 -C.sub.10 aryl-C.sub.2 -C.sub.6 -alkenyl group, a C.sub.2 -C.sub.6 alkynyl group, a C.sub.3 -C.sub.7 cycloalkyl group, a C.sub.3 -C.sub.7 cycloalkyl-C.sub.1 -C.sub.6 -alkyl group, a C.sub.5 -C.sub.7 cycloalkenyl-C.sub.1 -C.sub.6 -alkyl group or a halogeno-C.sub.1 -C.sub.6 -alkyl group; R.sup.2 and R.sup.3 are the same or different and each represents a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.6 -C.sub.10 aryl group; R.sup.4 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group; R.sup.5 represents a C.sub.6 -C.sub.

Abstract: This invention relates to a 8-trifluoromethylquinolinecaboxylic acid derivative represented by the following formula (I): ##STR1## (wherein R.sup.1 represents a lower alkyl group, a halogeno-lower alkyl group or a cycloalkyl group, R.sup.2 represents a phenyl group which may be substituted by R.sup.0, a 5-membered or 6-membered aromatic heteromonocyclic ring group containing 1 or 2 hetero atoms selected from N, O and S, which may be substituted by R.sup.0, or an aromatic heterocyclic fused ring group in which the said aromatic heteromonocyclic ring group and a benzene ring are fused, R.sup.0 represents a group selected from a halogen, a lower alkyl, a fluorine-substituted lower alkyl, a lower alkoxy or a lower alkylthio, R.sup.3 represents hydrogen or a lower alkyl group, and m represents an integer of 2 or 3.) or a pharmaceutically acceptable salt thereof or an ester thereof.

Abstract: Compounds of formula (I) and (II): ##STR1## ?wherein R is hydrogen, halogen or alkyl; R.sup.1 is alkyl, amino or substituted amino; R.sup.2 is optionally substituted phenyl; R.sup.3 is hydrogen, halogen or optionally substituted alkyl; R.sup.4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl! have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

Abstract: Disclosed are an aryl group- or heterocyclic group-substituted aminoquinolone compound represented by the formula (Ia), (Ib) or (Ic): ##STR1## wherein each of the substitutents are defined in the specification, or a salt of the compound, and an AIDS curing agent containing the same as an effective ingredient.

Abstract: A pyrimidine derivative represented by the formula (II) or (III): ##STR1## (wherein R.sup.1 and R.sup.2 each represent H, a halogen, amino, nitro, an unsubstituted or substituted alkyl, an alkoxy or an alkoxycarbonyl, or R.sup.1 and R.sup.2 are bonded together to form an unsubstituted or substituted alkylene; R.sup.3 represents an aralkyl or a hetero aromatic ring type-alkyl, R.sup.4 represents H or acyl, R.sup.5 represents H, OH or an alkoxy, R.sup.6 represents H, a halogen, an alkyl or an alkoxy, X represents --CH=, --CH=CH--(CH.sub.2).sub.p --, --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --(CH.sub.2).sub.p --, Y represents =CH-- (CH.sub.2).sub.p --, --CH.sub.2 --(CH.sub.2).sub.p --, a single bond or a double bond, p represents 0 or 1, and . . . represents a single bond or a double bond),and a salt thereof have selective acetylcholinesterase-inhibiting activities and selective A type monoamine oxidase-inhibiting activities, and are useful as an antidepressant and an agent for curing senile dementia.

Abstract: This invention relates to a compound (a quinoline derivative) represented by the formula (I): ##STR1## The quinoline derivative of this invention has a strong leukotriene antagonistic action and is extremely useful as an antiallergic medicine and an anti-inflammatory medicine.

Abstract: Disclosed are an aryl group- or heterocyclic group-substituted aminoquinolone compound represented by the formula (Ia), (Ib) or (Ic): ##STR1## wherein each of the substitutents are defined in the specification, or a salt of the compound, and an AIDS curing agent containing the same as an effective ingredient.

Abstract: Compounds of formula (I): ##STR1## (in which: R.sup.1 represents fluorinated methoxy: R.sup.2 represents a nitrogen-containing heterocyclic group and R.sup.3 represents hydrogen or amino) and pharmaceutically acceptable salts, esters and amides thereof are valuable antibacterial agents, which may be prepared by reacting a compound similar to that of formula (I) but in which R.sup.2 is replaced by a halogen atom with a compound providing the required group R.sup.2.

Abstract: Compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.

Abstract: Compounds of formula (I): ##STR1## (in which: R.sup.1 represents fluorinated methoxy; R.sup.2 represents a nitrogen-containing heterocyclic group and R.sup.3 represents hydrogen or amino) and pharmaceutically acceptable salts, esters and amides thereof are valuable antibacterial agents, which may be prepared by reacting a compound similar to that of formula (I) but in which R.sup.2 is replaced by a halogen atom with a compound providing the required group R.sup.2.

Abstract: Compounds of formula (I): ##STR1## (in which: R.sup.1 represents fluorinated methoxy; R.sup.2 represents a nitrogen-containing heterocyclic group and R.sup.3 represents hydrogen or amino) and pharmaceutically acceptable salts, esters and amides thereof are valuable antibacterial agents, which may be prepared by reacting a compound similar to that of formula (I) but in which R.sup.2 is replaced by a halogen atom with a compound providing the required group R.sup.2.

Abstract: Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.

Abstract: Compounds of formula (I): ##STR1## (in which: R.sup.1 represents fluorinated methoxy; R.sup.2 represents a nitrogen-containing heterocyclic group and R.sup.3 represents hydrogen or amino) and pharmaceutically acceptable salts, esters and amides thereof are valuable antibacterial agents, which may be prepared by reacting a compound similar to that of formula (I) but in which R.sup.2 is replaced by a halogen atom with a compound providing the required group R.sup.2.

Abstract: Compounds of formula (I): ##STR1## (in which R.sup.1 is alkoxy, R is alkyl, haloalkyl, alkylamino, cycloalkyl or optionally substituted phenyl, X is chlorine or fluorine and Y is selected from certain specific heterocycles) have excellent antibacterial activity. They may be prepared by introducing the group represented by Y into the corresponding compound in which Y is replaced by a halogen atom.

Abstract: Compounds of formula (I): ##STR1## (wherein R.sup.1 and R.sup.2 are hydroxy, alkoxy, aryloxy or acyloxy or R.sup.2 is hydrogen, R.sup.3 is hydrogen or alkyl and R.sup.4 and R.sup.5 are hydrogen or various organic substituents) have valuable antidepressant activity and may be used in the treatment of mental depression.

Abstract: Biochemical optical resolution of DL-tryptophans in which DL-tryptophan amides are interacted with the culture products, or their treated products, of a microorganism capable of producing amidase is described. L-Tryptophan amides in racemic DL-tryptophan amides are asymmetrically hydrolyzed to form optically active L-tryptophans at a high yield and almost all D-tryptophan amides remain without being subjected to hydrolysis. The resultant D-tryptophan amides are readily hydrolyzed, after separating L-tryptophans, to form optically active D-tryptophans at a high yield.

Abstract: Biochemical optical resolution of DL-tryptophanes in which DL-tryptophane amides are interacted with the culture products, or their treated products, of a microorganism capable of producing amidase is described. L-tryptophane amides in racemic DL-tryptophane amides are asymmetrically hydrolyzed to form optically active L-tryptophanes at a high yield and almost all D-tryptophane amides remain without being subjected to hydrolysis. The resultant D-tryptophane amides are readily hydrolyzed, after separating L-tryptophanes, to form optically active D-tryptophanes at a high yield.

Abstract: Biochemical optical resolution of DL-.alpha.-methylphenyl alanines in which DL-.alpha.-methylphenyl alanine amides are interacted with the culture products, or their treated products, of a microorganism capable of producing amidase is described. L-.alpha.-methylphenyl alanines having the general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 may be independently a hydrogen atom or lower alkyl groups, or R.sub.1 and R.sub.2 may be alkylene groups combined together to form 5 through 8-membered rings is produced by the steps of:(a) making a DL-.alpha.-methylphenyl alanine amide having the general formula (II): ##STR2## wherein R.sub.1 and R.sub.2 are the same as defined above, interact with the culture product of a microorganism capable of producing enzyme catalyzing the hydrolysis of L-isomer of DL-.alpha.-methylphenyl alanine amides or the treated product thereof, whereby asymmetric hydrolysis of an L-.alpha.-methylphenyl alanine amide is effected; and(b) separating the resultant L-.alpha.